Mechanism of action of AuraSTOP
Mechanism of action of the 5-HTP
5-HTP, extracted from the seeds of Griffonia simplicifolia, è is metabolized to kynurenic acid which antagonizes the excitatory action of glutamic acid, even at a central level, through the blocking of the activity of the NMDA receptor, which is hyperactive during the migraine attack. NMDA (N-Methyi-D-Aspartate) is a post-synaptic glutaminergic receptor that is involved in peripheral and central sensitization1.
Mechanism of action of magnesium
It inhibits the progression of cortical spreading depression (CSD), the underlying phenomenon of the aura. Magnesium regulates the state of neuronal excitability. An optimal intracellular concentration of magnesium acts as a physiological Ca-antagonist, limiting the “toxic” effects of intracellular excess Ca, while reduced magnesium concentrations favor the formation of free radicals and toxic concentrations of nitric oxide, important triggers for migraine crises. Therefore, magnesium may inhibit NMDA receptor activity, reducing excitatory glutamatergic signaling and the neurogenic inflammation associated with migraine.2,3.
Mechanism of Action of Tanacetum parthenium
It is a perennial herbaceous plant, a member of the family of Compositeae that thanks to its main active component, the parthenolide, interacts with the processes involved in the development of the aura. Parthenolide inhibits TRP (Transient Receptor Potential Channels) receptor and the consequent release of CGRP (Calcitonin gene-related peptide) from the perivascular terminals of the sensory neurons. In addition, parthenolide is a very powerful inhibitor of NOS expression (nitric oxide synthase) and the consequent synthesis of nitric oxide. Toxic concentrations of nitric oxide and free radicals are considered potential triggers of neurogenic inflammation and migraine attacks.4-5.
1. Louis et al. Kynurenic acid: a neuroprotective metabolite with key roles in brain health and immune function. Cardiometabolic disease 2024.
2. Dominguez LJ., et al. Magnesium and migraine. Nutrients 2025;17(4),725.
3. Vink R., et al. Magnesium in the central nervous system.
4. Materazzi S., et al. Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel. Pain. 2013;154(12):2750-2758.
5. Sprenger T., et al. Current prophylactic medications for migraiine and their potential machenisms of action. Neurotherapeutics. 2018;15(2):313-323
Benefits in Migraine Aura
Treatment of migraine aura
(Dalla Volta G., et al. 2018)
From a study conducted on 200 individuals, aged between 18 and 54 years, diagnosed with migraine with aura, characterized by at least three episodes of aura per year, each lasting 20 minutes, the data collected showed that Aurastop produced a significant reduction in the duration of the aura (from 43.2 ± 19.3 minutes in the pre-treatment period to 18.2 ± 10.3 minutes during treatment) and the degree of disability: from level 5 to a level 2 on a scale from 0 to 5.
After the integration of Aurastop, significant changes were observed in the characteristics of the migraine aura, with an evident reduction in its complexity and somatosensory manifestations. There was also a significant reduction in headache frequency crises, in the severity and duration of pain.
Prevention of episodic migraine without aura
(Mainardi F., Merlo P., et al. 2018)
An open study of 80 subjects, aged between 19 and 60, evaluated the efficacy and safety of AuraSTOP in the prophylactic treatment of aura-free episodic migraine. The results obtained showed a reduction in the days of persistence of migraine (from 9.1 ± 2 days before treatment to 3.2 ± 1.8 after treatment), a reduction in the monthly frequency of attacks (from 6 ± 1.2 attacks before treatment at 2.4 ± 1.1 after treatment) and pain intensity and, finally, a significant reduction in the number of doses of analgesic drugs. The product was safe and well tolerated.
Prevention of High-Frequency Migraine With Aura
(Volta G.D., Zavarise P., Perego L., Pezzini A., 2018)
A study published in 2018 evaluated the efficacy of AuraSTOP in the prevention of migraine with aura in patients with high frequency of attacks. 18 patients were enrolled, all diagnosed with aura migraines for at least 6 months and a monthly attack frequency of between 5 and 20 episodes. Significant improvements were observed and the following results were obtained: reduction in the frequency of attacks (reduction from 50% to 70%), reduction of aura episodes (438 in the 3 months pre-treatment vs 48 during), reduction in the duration of the aura (from 42 ± 1.2 minutes before treatment to 18 ± 1.1 minutes after treatment), decreased disability (94.5% of patients reported a reduction from 4 to 1 point) and, finally, a reduction in the intensity of headache.